BR112014024287A2 - composições e métodos para a prevenção e tratamento do derrame vascular induzido por mastócitos - Google Patents

composições e métodos para a prevenção e tratamento do derrame vascular induzido por mastócitos

Info

Publication number
BR112014024287A2
BR112014024287A2 BR112014024287-9A BR112014024287A BR112014024287A2 BR 112014024287 A2 BR112014024287 A2 BR 112014024287A2 BR 112014024287 A BR112014024287 A BR 112014024287A BR 112014024287 A2 BR112014024287 A2 BR 112014024287A2
Authority
BR
Brazil
Prior art keywords
treatment
methods
prevention
compositions
vascular leakage
Prior art date
Application number
BR112014024287-9A
Other languages
English (en)
Inventor
N. Abraham Soman
L. St. John Ashley
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261616062P priority Critical
Priority to US61/616,062 priority
Application filed by Duke University filed Critical Duke University
Priority to PCT/US2013/032553 priority patent/WO2013148366A1/en
Publication of BR112014024287A2 publication Critical patent/BR112014024287A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/175Bunyaviridae, e.g. California encephalitis virus, Rift valley fever virus, Hantaan virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/18Togaviridae; Flaviviridae
    • G01N2333/183Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • G01N2333/5412IL-6
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433Serine endopeptidases (3.4.21)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/26Infectious diseases, e.g. generalised sepsis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

resumo “composições e métodos para a prevenção e tratamento do derrame vascular induzido por mastócitos” são divulgados aqui, métodos de diagnóstico e tratamento de doença infecciosa caracterizada por uma patologia que envolve hemorragia ou derrame vascular patológico.
BR112014024287-9A 2012-03-27 2013-03-15 composições e métodos para a prevenção e tratamento do derrame vascular induzido por mastócitos BR112014024287A2 (pt)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201261616062P true 2012-03-27 2012-03-27
US61/616,062 2012-03-27
PCT/US2013/032553 WO2013148366A1 (en) 2012-03-27 2013-03-15 Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage

Publications (1)

Publication Number Publication Date
BR112014024287A2 true BR112014024287A2 (pt) 2018-05-08

Family

ID=49261101

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014024287-9A BR112014024287A2 (pt) 2012-03-27 2013-03-15 composições e métodos para a prevenção e tratamento do derrame vascular induzido por mastócitos

Country Status (6)

Country Link
US (2) US9730921B2 (pt)
AU (1) AU2013240220B2 (pt)
BR (1) BR112014024287A2 (pt)
IN (1) IN2014KN02323A (pt)
SG (1) SG11201406142XA (pt)
WO (1) WO2013148366A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301999B2 (en) 2009-09-28 2016-04-05 Duke University Peptide, adjuvants, vaccines, and methods of use
SG11201406142XA (en) 2012-03-27 2014-10-30 Univ Duke Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
RU2015134422A (ru) 2013-03-13 2017-04-18 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении васкулита
ES2654093T3 (es) 2013-03-13 2018-02-12 Inflammatory Response Research, Inc. Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes
CN103630645B (zh) * 2013-11-27 2016-08-17 中国检验检疫科学研究院 一种测定化妆品中苯海拉明含量的液相色谱-串联质谱法
JP6382997B2 (ja) 2014-02-07 2018-08-29 エクセセーラ ファーマシューティカルズ インコーポレイテッド 治療用化合物および組成物
AU2015213678C1 (en) 2014-02-10 2019-03-21 Respivant Sciences Gmbh Mast cell stabilizers treatment for systemic disorders
DK3104854T3 (da) 2014-02-10 2020-05-04 Respivant Sciences Gmbh MAST-CELL STABILIZERS FOR HEALTH DISEASE TREATMENT
CN103735546A (zh) * 2014-02-11 2014-04-23 中国人民解放军军事医学科学院放射与辐射医学研究所 4-氧代-8-[4-(4-苯基丁氧基)苯甲酰氨基]-2-四氮杂茂-4h-1-苯并吡喃-半水合物的新用途
DE102014111892A1 (de) * 2014-08-20 2016-02-25 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung einer Infektion mit dem Hantavirus
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017096049A1 (en) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Materials for cathepsin b enhancement and methods of use
EP3487875A4 (en) * 2016-07-19 2020-02-12 Arete Discoveries, Inc. BIOMARKERS FOR THE DETECTION AND TREATMENT OF DISORDERS ASSOCIATED WITH THE ACTIVITY OF MASTOCYTES
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングRespivant Sciences Gmbh 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
CN106511346A (zh) * 2016-12-08 2017-03-22 上海市公共卫生临床中心 一种可用于抑制寨卡病毒感染的小分子药物及其应用
CN108872405B (zh) * 2017-05-11 2021-06-01 武汉先路医药科技股份有限公司 一种洛度沙胺氨丁三醇有关物质的hplc分析检测方法
MX2018011699A (es) 2018-09-26 2019-07-24 Federico Amezcua Amezcua Composicion farmaceutica sinergica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1.
CN110237074A (zh) * 2019-07-25 2019-09-17 中国科学院武汉病毒研究所 贝尼地平在制备预防和/或治疗布尼亚病毒感染性疾病药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2061862A1 (en) 1991-03-04 1992-09-05 Jonathan Duvick Natural and synthetic proteins with inhibitory activity towards pathogenic microorganisms
AU2514592A (en) 1991-08-21 1993-03-16 Board Of Regents, The University Of Texas System Methods and compositions for modulating g protein action
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
DE10055375A1 (de) * 2000-11-08 2002-05-23 Infineon Technologies Ag Auswerteschaltung für Wechselspannungsimpulse
IL140473D0 (en) 2000-12-21 2002-02-10 Allergene Ltd Anti-allergic complex molecules
EP1601380A1 (en) 2003-02-13 2005-12-07 Licentia OY Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
WO2004071532A1 (en) 2003-02-13 2004-08-26 Licentia Oy Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses
US8076059B2 (en) 2003-04-16 2011-12-13 Duke University Adjuvant capable of specifically activating the adaptive immune response
GB0427267D0 (en) 2004-12-13 2005-01-12 Maria Teresa De Magistris Peptide adjuvants
US8232240B2 (en) * 2005-02-23 2012-07-31 The Brigham And Women's Hospital, Inc. Inhibitors of enveloped virus infectivity
EP2187914A2 (en) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Astressin and beta-endorphin for use as therapeutic agents
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
US9301999B2 (en) 2009-09-28 2016-04-05 Duke University Peptide, adjuvants, vaccines, and methods of use
MX2012011629A (es) 2010-04-07 2013-03-05 Abbvie Inc PROTEINS OF UNION TO TNF-ALFA.
SG11201406142XA (en) 2012-03-27 2014-10-30 Univ Duke Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage

Also Published As

Publication number Publication date
AU2013240220B2 (en) 2017-07-20
AU2013240220A1 (en) 2014-10-16
SG11201406142XA (en) 2014-10-30
US20170368050A1 (en) 2017-12-28
WO2013148366A1 (en) 2013-10-03
US20150038530A1 (en) 2015-02-05
IN2014KN02323A (pt) 2015-05-01
US9730921B2 (en) 2017-08-15
US10668059B2 (en) 2020-06-02

Similar Documents

Publication Publication Date Title
BR112014024287A2 (pt) composições e métodos para a prevenção e tratamento do derrame vascular induzido por mastócitos
CA2865011C (en) Methods and compositions for treating huntington's disease
EA030811B1 (ru) COMPOUNDS APPLICABLE AS IMMUNOMODULATORS
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
CR20150020A (es) Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
MX2015003228A (es) COMPOSITIONS OF SEMIFLUORATED ALKANS.
BR112015014555A2 (pt) composições pesticidas e processos relacionados a isso
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
CR20120202A (es) Métodos y composiciones para tratar cáncer
NI201400022A (es) Composición farmacéutica que comprende un ciclopolisacárido
GEP20156347B (en) Benzodioxane inhibitors of leukotriene production
WO2011106322A3 (en) Biomarkers for acute ischemic stroke
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
EA201200046A1 (ru) Новые соединения, фармацевтическая композиция и связанные с ними способы
ECSP14027694A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
BR112015030203A2 (pt) moléculas pequenas inibidores da fibrose
BR112018071602A2 (pt) compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase
BR112012019351A2 (pt) composição de combinação, que inclui como ingredientes ativos l-carnitina ou propionil l-carnitina, para a prevenção ou tratamento de insuficiência venosa crônica.
BR112016006556A2 (pt) arranjos detectáveis, sistemas para diagnóstico, e métodos para produzir e usar os mesmos
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
BR112015006727A2 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
BR112018000589A2 (pt) composição de tratamento de cabelo, método para o tratamento de cabelo e utilização de uma composição

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 8A ANUIDADE.